Form 8-K · Current Report · Filed 2026-05-20
Roivant Sciences Announces $2.25 Billion Settlement with Moderna and Reports Q4 2026 Financial Results
Roivant Sciences Ltd. reported its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provided a business update. The company announced a $2.25 billion global settlement with Moderna, ending all pending U.S. and international patent-infringement litigation. Roivant also provided updates on its clinical trials, including positive results from the IMVT-1402 trial in difficult-to-treat rheumatoid arthritis and the granting of Breakthrough Therapy Designation for brepocitinib in cutaneous sarcoidosis. The company reported consolidated cash, cash equivalents, and marketable securities of $4.3 billion as of March 31, 2026.
- Filer
- Roivant Sciences Ltd ROIV · NASDAQ
- Filed
- Accession
- 0001635088-26-000060
- CIK
- 0001635088
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$28.21
Next session
+9.5%
Since filing
+22.8%
Latest close
$34.64
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ROIV reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, ROIV insiders reported 38 Form 4 transactions — net selling of $198.0M.
About Roivant Sciences Ltd
Roivant Sciences Ltd is a biopharmaceutical company focused on developing and commercializing innovative therapies through a unique model that emphasizes rapid and efficient drug delivery. As a platform company, Roivant Sciences incubates subsidiaries known as 'Vants,' each concentrating on a specific therapeutic area. This model allows Roivant to prioritize development of pharmaceuticals in critical areas, including neurology, oncology, immunology, and others. Roivant’s approach facilitates agility in drug development, enabling each Vant to operate semi-autonomously to accelerate research and commercialization efforts. By leveraging technology and data analytics, Roivant enhances drug discovery processes and optimizes clinical trials. In the pharmaceutical industry, Roivant Sciences represents a forward-thinking entity that addresses unmet medical needs by transforming the traditional paradigms of drug development. Its initiatives have substantial implications for healthcare, potentially altering treatment landscapes and improving patient outcomes globally. Founded in 2014 and headquartered in New York City, Roivant is a notable example of innovation-driven pharmaceutical enterprise in the financial market.
Never miss another ROIV filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.